OBI Pharma Statistics

Total Valuation

OBI Pharma has a market cap or net worth of TWD 3.76 billion. The enterprise value is 4.20 billion.

Market Cap	3.76B
Enterprise Value	4.20B

Important Dates

The next estimated earnings date is Wednesday, August 12, 2026.

Earnings Date	Aug 12, 2026
Ex-Dividend Date	n/a

Share Statistics

OBI Pharma has 131.58 million shares outstanding. The number of shares has increased by 3.76% in one year.

Current Share Class	131.58M
Shares Outstanding	131.58M
Shares Change (YoY)	+3.76%
Shares Change (QoQ)	+11.64%
Owned by Insiders (%)	6.44%
Owned by Institutions (%)	2.95%
Float	86.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	75.75
PB Ratio	1.68
P/TBV Ratio	2.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.12
EV / Sales	84.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.41

Financial Position

The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.21.

Current Ratio	3.44
Quick Ratio	2.48
Debt / Equity	0.21
Debt / EBITDA	n/a
Debt / FCF	-0.27
Interest Coverage	-160.80

Financial Efficiency

Return on equity (ROE) is -67.84% and return on invested capital (ROIC) is -35.25%.

Return on Equity (ROE)	-67.84%
Return on Assets (ROA)	-34.03%
Return on Invested Capital (ROIC)	-35.25%
Return on Capital Employed (ROCE)	-83.40%
Weighted Average Cost of Capital (WACC)	4.57%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.01
Inventory Turnover	5.49

Taxes

Income Tax	-1.33M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.75% in the last 52 weeks. The beta is 0.11, so OBI Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.11
52-Week Price Change	-57.75%
50-Day Moving Average	34.94
200-Day Moving Average	48.95
Relative Strength Index (RSI)	24.46
Average Volume (20 Days)	572,809

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OBI Pharma had revenue of TWD 49.68 million and -1.98 billion in losses. Loss per share was -15.78.

Revenue	49.68M
Gross Profit	-89.02M
Operating Income	-2.11B
Pretax Income	-2.21B
Net Income	-1.98B
EBITDA	-1.95B
EBIT	-2.11B
Loss Per Share	-15.78

Full Income Statement

Balance Sheet

The company has 802.32 million in cash and 463.99 million in debt, with a net cash position of 338.33 million or 2.57 per share.

Cash & Cash Equivalents	802.32M
Total Debt	463.99M
Net Cash	338.33M
Net Cash Per Share	2.57
Equity (Book Value)	2.24B
Book Value Per Share	9.98
Working Capital	804.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.71 billion and capital expenditures -31.81 million, giving a free cash flow of -1.74 billion.

Operating Cash Flow	-1.71B
Capital Expenditures	-31.81M
Depreciation & Amortization	158.21M
Net Borrowing	-23.88M
Free Cash Flow	-1.74B
FCF Per Share	-13.23

Full Cash Flow Statement

Margins

Gross Margin	-179.19%
Operating Margin	-4,250.69%
Pretax Margin	-4,451.32%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OBI Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.76%
Shareholder Yield	-3.76%
Earnings Yield	-52.66%
FCF Yield	-46.26%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 27, 2026. It was a reverse split with a ratio of 0.5.

Last Split Date	Jan 27, 2026
Split Type	Reverse
Split Ratio	0.5

Scores

Altman Z-Score	n/a
Piotroski F-Score	2